thrombolytic drug

(redirected from Thrombolytics)
Also found in: Medical.

thrombolytic drug

(thrŏm'bəlĭt`ĭk) or

clot-dissolving drug,

substance, such as streptokinase or tissue plasminogen activator (tPA), that causes the breakdown of blood clots (see thrombosisthrombosis
, obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted.
..... Click the link for more information.
) that obstruct the flow of blood through the vessels. Its uses include injection during or shortly after a heart attack or strokestroke,
destruction of brain tissue as a result of intracerebral hemorrhage or infarction caused by thrombosis (clotting) or embolus (obstruction in a blood vessel caused by clotted blood or other foreign matter circulating in the bloodstream); formerly called apoplexy.
..... Click the link for more information.
 (see infarctioninfarction,
blockage of blood circulation to a localized area or organ of the body resulting in tissue death. Infarctions commonly occur in the spleen, kidney, lungs, brain, and heart.
..... Click the link for more information.
) to prevent clots from blocking blood flow to the heart muscle or brain.
References in periodicals archive ?
"Currently available infusion catheters used to treat PE and other large clots are not able to rapidly restore blood flow through the thrombus and allow for only limited radial diffusion of exogenously administered thrombolytics like r-tPA into a clot," said Marv Woodall, Chairman & CEO of Thrombolex.
In this review, we will talk about thrombolytic therapy, which is the primary treatment for patients with especially life-threatening high-risk PTE and recent developments in this area.
International guidelines no longer consider CPR as a contraindication for thrombolysis as the thrombolytic therapy during reanimation can contribute to stabilization in patients with CA caused by MPE.
Prolonged infusions of low-dose thrombolytics in elderly patients with prosthetic heart valve thrombosis: Clinical and Applied Thrombosis/Hemostasis; 2017; 23(3): 241-47.
However, these studies had various limitations such as late administration of thrombolytics and small sample size.
113 (56.5%) were treated with thrombolytic therapy, 87(43.5%) did not receive thrombolytic therapy.
However, starting treatments such as thrombolytic therapy that is solely considered according to ECG may be a wrong decision.
[1] Intervention with thrombolytic agents in AMI is an effective means of limiting myocardial damage.
Thrombolytics and surgical embolectomy are considered in patients presenting with shock and in those with refractory hypoxia.
Background: Despite significant efforts to improve thrombolytic use in the United States, only a small number of patients with ischemic stroke are currently treated.
Limitations in thrombolytic therapy in acute ischemic stroke.
Their topics include in vivo models for evaluating antithrombotics and thrombolytics, principle and practice in novel anticoagulant therapy, antithrombotic effects of naturally derived products on coagulation and platelet function, potential therapeutic and diagnostic implications of adhesion molecules, and the diagnosis and management of sickle cell disorders.